631 related articles for article (PubMed ID: 24803537)
101. Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice.
Johnson BL; d'Alincourt Salazar M; Mackenzie-Dyck S; D'Apuzzo M; Shih HP; Manuel ER; Diamond DJ
PLoS One; 2019; 14(9):e0221810. PubMed ID: 31490946
[TBL] [Abstract][Full Text] [Related]
102. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
103. The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and pancreatic carcinogenesis.
Brunet M; Vargas C; Fanjul M; Varry D; Hanoun N; Larrieu D; Pieruccioni L; Labrousse G; Lulka H; Capilla F; Ricard A; Selves J; Couvelard A; Gigoux V; Cordelier P; Guillermet-Guibert J; Dufresne M; Torrisani J
J Pathol; 2024 Jun; ():. PubMed ID: 38924548
[TBL] [Abstract][Full Text] [Related]
104. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.
Martínez-Bosch N; Fernández-Barrena MG; Moreno M; Ortiz-Zapater E; Munné-Collado J; Iglesias M; André S; Gabius HJ; Hwang RF; Poirier F; Navas C; Guerra C; Fernández-Zapico ME; Navarro P
Cancer Res; 2014 Jul; 74(13):3512-24. PubMed ID: 24812270
[TBL] [Abstract][Full Text] [Related]
105. The Janus kinase 1 is critical for pancreatic cancer initiation and progression.
Shrestha H; Rädler PD; Dennaoui R; Wicker MN; Rajbhandari N; Sun Y; Peck AR; Vistisen K; Triplett AA; Beydoun R; Sterneck E; Saur D; Rui H; Wagner KU
Cell Rep; 2024 May; 43(5):114202. PubMed ID: 38733583
[TBL] [Abstract][Full Text] [Related]
106. Oral bacteria accelerate pancreatic cancer development in mice.
Saba E; Farhat M; Daoud A; Khashan A; Forkush E; Menahem NH; Makkawi H; Pandi K; Angabo S; Kawasaki H; Plaschkes I; Parnas O; Zamir G; Atlan K; Elkin M; Katz L; Nussbaum G
Gut; 2024 Apr; 73(5):770-786. PubMed ID: 38233197
[TBL] [Abstract][Full Text] [Related]
107. LncRNA HULC augments high glucose-associated pancreatic cancer progression and drug resistance by enhancing YAP activity and autophagy.
Sharma A; Chowdhury S; Mukherjee S; Chowdhury R
Biol Cell; 2024 Jul; ():e202400034. PubMed ID: 38949568
[TBL] [Abstract][Full Text] [Related]
108. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.
Mehner C; Miller E; Khauv D; Nassar A; Oberg AL; Bamlet WR; Zhang L; Waldmann J; Radisky ES; Crawford HC; Radisky DC
Mol Cancer Res; 2014 Oct; 12(10):1430-9. PubMed ID: 24850902
[TBL] [Abstract][Full Text] [Related]
109. Multidimensional screening of pancreatic cancer spheroids reveals vulnerabilities in mitotic and cell-matrix adhesion signaling that associate with metastatic progression and decreased patient survival.
Aquino AF; Runa F; Shoma JF; Todd A; Wallace M; de Barros NR; Kelber JA
Biochem Biophys Res Commun; 2024 Apr; 703():149575. PubMed ID: 38382357
[TBL] [Abstract][Full Text] [Related]
110. KRAS promotes GLI2-dependent transcription during pancreatic carcinogenesis.
Sigafoos AN; Tolosa EJ; Carr RM; Fernández-Barrena MG; Almada LL; Pease DR; Hogenson TL; Raja Arul GL; Mousavi F; Sen S; Vera RE; Marks DL; Flores LF; LaRue-Nolan KC; Wu C; Bamlet WR; Vrabel AM; Sicotte H; Schenk EL; Smyrk TC; Zhang L; Rabe KG; Oberg AL; Zaphiropoulos PG; Chevet E; Graham RP; Hagen CE; Pasca di Magliano M; Elsawa SF; Pin CL; Mao J; McWilliams RR; Fernandez-Zapico ME
Cancer Res Commun; 2024 Jun; ():. PubMed ID: 38896052
[TBL] [Abstract][Full Text] [Related]
111. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract][Full Text] [Related]
112. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
Wasko UN; Jiang J; Curiel-Garcia A; Wang Y; Lee B; Orlen M; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Dalton T; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs W; Amparo AA; Hibshman PS; Rees MG; Ronan MM; Roth JA; Bakir B; Badgley MA; Chabot JA; Kluger MD; Manji GA; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Aguirre AJ; Der CJ; Vonderheide RH; Stanger BZ; Singh M; Olive KP
bioRxiv; 2023 Dec; ():. PubMed ID: 38105998
[TBL] [Abstract][Full Text] [Related]
113. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.
Huang YK; Cheng WC; Kuo TT; Yang JC; Wu YC; Wu HH; Lo CC; Hsieh CY; Wong SC; Lu CH; Wu WL; Liu SJ; Li YC; Lin CC; Shen CN; Hung MC; Lin JT; Yeh CC; Sher YP
Nat Cancer; 2024 Mar; 5(3):400-419. PubMed ID: 38267627
[TBL] [Abstract][Full Text] [Related]
114. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer.
Maurer HC; Garcia-Curiel A; Holmstrom SR; Castillo C; Palermo CF; Sastra SA; Andren A; Zhang L; Le Large TYS; Sagalovskiy I; Ross DR; Wong W; Shaw K; Genkinger J; Manji GA; Iuga AC; Schmid RM; Johnson K; Badgley MA; Lyssiotis CA; Shah Y; Califano A; Olive KP
bioRxiv; 2024 Jun; ():. PubMed ID: 36993718
[TBL] [Abstract][Full Text] [Related]
115. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.
Salas-Escabillas DJ; Hoffman MT; Moore JS; Brender SM; Wen HJ; Benitz S; Davis ET; Long D; Wombwell AM; Steele NG; Sears RC; Matsumoto I; DelGiorno KE; Crawford HC
bioRxiv; 2024 Apr; ():. PubMed ID: 38405804
[TBL] [Abstract][Full Text] [Related]
116. Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.
Brambillasca S; Cera MR; Andronache A; Dey SK; Fagá G; Fancelli D; Frittoli E; Pasi M; Robusto M; Varasi M; Scita G; Mercurio C
Biomed Pharmacother; 2024 Jun; 177():116991. PubMed ID: 38906021
[TBL] [Abstract][Full Text] [Related]
117. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma.
Fukuda J; Kosuge S; Satoh Y; Sekiya S; Yamamura R; Ooshio T; Hirata T; Sato R; Hatanaka KC; Mitsuhashi T; Nakamura T; Matsuno Y; Hatanaka Y; Hirano S; Sonoshita M
Cancer Sci; 2024 Apr; 115(4):1333-1345. PubMed ID: 38320747
[TBL] [Abstract][Full Text] [Related]
118. Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer.
Lee MJ; Cho JY; Bae S; Jung HS; Kang CM; Kim SH; Choi HJ; Lee CK; Kim H; Jo D; Paik YK
J Proteome Res; 2024 Mar; 23(3):985-998. PubMed ID: 38306169
[TBL] [Abstract][Full Text] [Related]
119. Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma.
Maia-Silva D; Cunniff PJ; Schier AC; Skopelitis D; Trousdell MC; Moresco P; Gao Y; Kechejian V; He XY; Sahin Y; Wan L; Alpsoy A; Liverpool J; Krainer AR; Egeblad M; Spector DL; Fearon DT; Dos Santos CO; Taatjes DJ; Vakoc CR
Nat Genet; 2024 Jun; ():. PubMed ID: 38886586
[TBL] [Abstract][Full Text] [Related]
120. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
